The FDA 510(k) clearance confirms substantial equivalence to Harvard-origin SmartPReP and validates Miracell’s integrated SMART M-CELL system, including the centrifuge and accompanying kits.

This clearance covers the entire integrated system, not just individual components, marking a differentiator from traditional centrifuge devices.

Miracell has received FDA clearance for the SMART M-CELL system and its BSC Blood Kit and BMSC Bone Marrow Kit, enabling automated concentration of Efficient Growth Factors from blood and bone marrow.

SMART M-CELL is designed to maximize cell viability and recovery, producing a multi-cell composition that includes growth factors, white blood cells, and SDF-1α for tissue regeneration.

The system automates extraction and concentration of Efficient Growth Factors from blood and bone marrow, delivering a multi-cell composition to support tissue regeneration.

Miracell holds a U.S. patent awarded in February 2024 for the centrifuge container used in SMART M-CELL, reinforcing intellectual property protections.

Miracell emphasizes that higher cell purity correlates with better performance and views theFDA clearance as the culmination of extensive R&D to push purity margins further.

Industry observers note a shift toward biologic, autologous cell- and growth-factor–based therapies for tissue repair rather than merely managing symptoms.

Miracell already operates in roughly 40 countries and ships SMART M-CELL worldwide, with regulatory work in Brazil and Taiwan and plans to accelerate U.S. expansion after the FDA clearance.

The company is pursuing additional regulatory approvals in Brazil and Taiwan while targeting rapid U.S. and global market expansion post-clearance.

Beyond musculoskeletal use, the technology has broad regenerative applications, including skin regeneration, diabetic ulcers, chronic wounds, vascular repair, and immune-related conditions.